Cargando…
Clinical efficacy and safety of Razumab® (CESAR) study: Our experience with the world's first biosimilar Ranibizumab
PURPOSE: The aim of this study was to evaluate the efficacy and safety of Razumab (the biosimilar Ranibizumab by Intas Pharmaceuticals Ltd.) for the treatment of chorioretinal vascular diseases such as diabetic macular edema (DME), choroidal neovascular membrane (CNVM), and macular edema secondary t...
Autores principales: | Verma, Lalit, Thulasidas, Mithun, Purohit, Ajay, Gupta, Avnindra, Narula, Ritesh, Talwar, Dinesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7933889/ https://www.ncbi.nlm.nih.gov/pubmed/33463589 http://dx.doi.org/10.4103/ijo.IJO_2516_20 |
Ejemplares similares
-
Giving anti-VEGF injections: an update from Burundi
por: Niyonzima, Jean Claude
Publicado: (2023) -
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey
por: Sheth, Jay U, et al.
Publicado: (2021) -
Effect of Decorin and Bevacizumab on oxygen-induced retinopathy in rat models: A comparative study
por: Duran Güler, Seda, et al.
Publicado: (2021) -
One-year outcomes of Aflibercept for refractory diabetic macular edema in Bevacizumab nonresponders
por: Salimi, Ali, et al.
Publicado: (2021) -
Real-World Safety Outcomes of Intravitreal Ranibizumab Biosimilar (Razumab) Therapy for Chorioretinal Diseases
por: Chakraborty, Debdulal, et al.
Publicado: (2021)